NADAC acquisition cost data for ACIPHEX DR 20 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 62856024330 | $21.40 | 2022-09-01 | Rx |
| 69784024330 | $21.40 | 2022-09-01 | Rx |
| 62856024330 | $21.40 | 2022-09-01 | Rx |
| 69784024330 | $21.40 | 2022-09-01 | Rx |
| 62856024330 | $21.40 | 2022-09-01 | Rx |
| 69784024330 | $21.40 | 2022-09-01 | Rx |
| 62856024330 | $21.40 | 2022-09-01 | Rx |
| 69784024330 | $21.40 | 2022-09-01 | Rx |
| 62856024330 | $21.40 | 2022-09-01 | Rx |
| 69784024330 | $21.40 | 2022-09-01 | Rx |
Generic: Rabeprazole Sodium | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $19.7M | 15,888 | 3,324 | $17.06 |
| 2020 | $18.1M | 13,926 | 2,940 | $16.99 |
| 2021 | $16.2M | 11,451 | 2,504 | $17.84 |
| 2022 | $15.9M | 9,439 | 2,140 | $20.27 |
| 2023 | $16.1M | 7,726 | 1,820 | $24.08 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $2.2M | 1,025 | 257 |
| California | $1.9M | 946 | 232 |
| New Jersey | $988.0K | 532 | 122 |
| Pennsylvania | $965.2K | 530 | 115 |
| Florida | $757.2K | 353 | 93 |
| North Carolina | $748.4K | 322 | 80 |
| Massachusetts | $688.1K | 270 | 60 |
| Connecticut | $665.3K | 256 | 61 |
| Texas | $663.4K | 337 | 78 |
| Wisconsin | $614.4K | 248 | 50 |
| Ohio | $563.9K | 302 | 63 |
| Illinois | $563.8K | 264 | 63 |
| Michigan | $422.6K | 212 | 50 |
| Arizona | $403.2K | 170 | 49 |
| Minnesota | $304.1K | 120 | 33 |
| Georgia | $266.7K | 137 | 33 |
| Indiana | $253.5K | 127 | 29 |
| Maryland | $248.7K | 123 | 30 |
| Virginia | $240.6K | 145 | 32 |
| Tennessee | $208.3K | 93 | 22 |
| Washington | $198.7K | 90 | 25 |
| New Hampshire | $184.0K | 65 | 17 |
| Kentucky | $142.7K | 57 | 12 |
| Colorado | $131.8K | 87 | 20 |
| South Carolina | $130.6K | 71 | 22 |
| Alabama | $127.1K | 51 | 12 |
| Oregon | $109.2K | 67 | 14 |
| Louisiana | $108.0K | 61 | 12 |
| West Virginia | $107.0K | 38 | N/A |
| Nebraska | $106.6K | 46 | 12 |
| Missouri | $96.3K | 61 | 12 |
| Maine | $93.5K | 40 | N/A |
| Kansas | $88.0K | 37 | N/A |
| Oklahoma | $88.0K | 35 | N/A |
| Utah | $80.2K | 44 | N/A |
| Arkansas | $79.6K | 44 | N/A |
| Delaware | $71.3K | 33 | N/A |
| Iowa | $63.2K | 26 | N/A |
| Nevada | $60.7K | 21 | N/A |
| Hawaii | $58.5K | 32 | N/A |
| Vermont | $54.8K | 20 | N/A |
| Alaska | $52.0K | 31 | N/A |
| Mississippi | $51.9K | 39 | N/A |
| New Mexico | $47.6K | 19 | N/A |
| Montana | $37.3K | 19 | N/A |
| South Dakota | $28.8K | 15 | N/A |
| Idaho | $27.3K | 21 | N/A |
| District of Columbia | $20.3K | 11 | N/A |
| Rhode Island | $13.5K | 11 | N/A |
| Wyoming | $9.3K | 12 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.